Shots:

• Shionogi and UBE Industries collaborates for development of anti-RS (respiratory syncytial) virus drugs to treat Respiratory Syncytial Virus (RSV) infection
• The focus of the agreement is to combine Shionogi’s drug discovery platform with UBE’s drug design technology for SAR (Structure-Activity Relationship) study
• UBE Industries’ Drug discovery platform uses polymer synthesis technology for the development of drug candidates in multiple therapeutic area

Ref: Shionogi | Image: Japan Products